File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. Cooperative Group Trials: comparing the outcomes of elderly to younger patients (pts)

TitleA pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. Cooperative Group Trials: comparing the outcomes of elderly to younger patients (pts)
Authors
Stinchcombe, TZhang, YVokes, ESchiller, JBradley, JCurran, WMovsas, BSchild, SClamon, GGovindan, RBlumenschein, GSocinski, MReady, NAkerley, WCohen, HPang, HMHWang, X
Issue Date2016
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 3-7 June 2016. In Journal of Clinical Oncology, 2016, v. 34 suppl., abstract no. 8508 How to Cite?
AbstractBACKGROUND: CCRT is the standard treatment (TRT) for stage 3 NSCLC. Elderly pts are common and may have increased toxicity and poorer results from CCRT. METHODS: We collected individual patient data (IPD) of pts who participated in cooperative group phase 2/3 trials of CCRT for stage 3A/3B pts from 1990-2012. We compared the overall survival (OS), progression-free survival (PFS), and adverse events (AE’s) for pts age ≥70 years (yrs) (elderly) vs. <70 yrs (younger). Unadjusted and adjusted Hazard Ratios (HRs) for survival time and their confidence intervals (CIs) were ...
DescriptionPoster Discussion Session: Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: abstract 8508
Persistent Identifierhttp://hdl.handle.net/10722/233594
ISSN
0732-183X
2021 Impact Factor: 50.717
2020 SCImago Journal Rankings: 10.482

 

DC FieldValueLanguage
dc.contributor.authorStinchcombe, T-
dc.contributor.authorZhang, Y-
dc.contributor.authorVokes, E-
dc.contributor.authorSchiller, J-
dc.contributor.authorBradley, J-
dc.contributor.authorCurran, W-
dc.contributor.authorMovsas, B-
dc.contributor.authorSchild, S-
dc.contributor.authorClamon, G-
dc.contributor.authorGovindan, R-
dc.contributor.authorBlumenschein, G-
dc.contributor.authorSocinski, M-
dc.contributor.authorReady, N-
dc.contributor.authorAkerley, W-
dc.contributor.authorCohen, H-
dc.contributor.authorPang, HMH-
dc.contributor.authorWang, X-
dc.date.accessioned2016-09-20T05:37:49Z-
dc.date.available2016-09-20T05:37:49Z-
dc.date.issued2016-
dc.identifier.citationThe 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 3-7 June 2016. In Journal of Clinical Oncology, 2016, v. 34 suppl., abstract no. 8508-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/233594-
dc.descriptionPoster Discussion Session: Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: abstract 8508-
dc.description.abstractBACKGROUND: CCRT is the standard treatment (TRT) for stage 3 NSCLC. Elderly pts are common and may have increased toxicity and poorer results from CCRT. METHODS: We collected individual patient data (IPD) of pts who participated in cooperative group phase 2/3 trials of CCRT for stage 3A/3B pts from 1990-2012. We compared the overall survival (OS), progression-free survival (PFS), and adverse events (AE’s) for pts age ≥70 years (yrs) (elderly) vs. <70 yrs (younger). Unadjusted and adjusted Hazard Ratios (HRs) for survival time and their confidence intervals (CIs) were ...-
dc.languageeng-
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncology-
dc.titleA pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. Cooperative Group Trials: comparing the outcomes of elderly to younger patients (pts)-
dc.typeConference_Paper-
dc.identifier.emailPang, HMH: herbpang@hku.hk-
dc.identifier.authorityPang, HMH=rp01857-
dc.description.naturepostprint-
dc.identifier.hkuros264714-
dc.identifier.volume34-
dc.identifier.issuesuppl.-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 161116-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats